The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money.

On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. This is the company’s investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus in healthy adults aged 18 to 40 years.

Copyright: iggyphoto / 123RF Stock Photo

The company anticipates reporting topline data from the study in the second half of 2027. The primary objective of the randomized, double-blind, placebo-controlled, dose-escalation, two-stage study is to assess the safety and tolerability of VAX-A1, while the secondary objective is to evaluate initial immunogenicity data.

Stage 1 will evaluate three dose levels compared to a placebo in approximately 12 adults. Following independent Data Safety Monitoring Board approval, Stage 2 will evaluate the same dose levels in approximately 68 adults.

Speaking about this development, Grant Pickering, CEO and Co-Founder of Vaxcyte, stated that initiation of the study represents an important milestone in addressing a significant global public health challenge with no approved vaccine. Furthermore, Jim Wassil, EVP and COO, noted that Group A Strep is responsible for a wide spectrum of diseases.

Vaxcyte Inc. (NASDAQ:PCVX) is a company involved in the development of next-generation vaccines that offer protection against threatening bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. (NASDAQ:PCVX) deploys innovative synthetic methods and advanced chemistry to produce complex, high-fidelity vaccines that contain enhanced immunological benefits.

While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.